Phase 2 Mesothelioma Trial, Recruiting NCT03007030 Sponsor: M.D. Anderson Cancer Center Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT03007030
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to give written agreement to take part, and you understand you can leave the study at any time without it affecting your regular medical care
  • If you are a woman, you are either past menopause for at least one year, have had a surgical procedure that means you cannot get pregnant, or you agree to use an approved form of birth control during the study and for at least 6 months after your last dose of the study drug
  • If you are a man (even if you have had a vasectomy), you agree to use a condom with spermicide or to completely avoid heterosexual sex during the study and for 6 months after your last dose of the study drug
  • Your blood test results show that your immune cells, platelets, and red blood cells are at acceptable levels (confirm with trial site)
  • Your liver and kidney function tests are within acceptable ranges (confirm with trial site)
  • You are able to carry out basic daily activities and care for yourself, even if you cannot do heavy physical work (confirm with trial site)
  • You have been diagnosed with malignant mesothelioma (any location in the body and any type are acceptable)
  • Your mesothelioma cannot be removed by surgery
  • Your cancer cells test positive for a protein called CD30
  • You may have had any amount of previous cancer treatment, or none at all
  • Your cancer can be measured using medical scans, and those scans were done within the last 28 days

Who may not be able to join:

  • You have had radiation treatment covering more than 25% of your bone marrow (for example, full pelvic radiation)
  • You have previously had a bone marrow or organ transplant from another person
  • You are currently pregnant or breastfeeding
  • You have taken another experimental drug within 14 days before joining the study
  • You have a serious physical or mental health condition that is likely to make it difficult to take part in the study
  • You have been diagnosed with another cancer within the past 2 years (exceptions may apply for certain skin cancers or some early-stage solid tumours), or a blood cancer within the past 3 years
  • You have had a serious allergic reaction to any part of the study drug, brentuximab vedotin
  • You are currently in prison or likely to be incarcerated during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Anne S Tsao, M.D. Anderson Cancer Center

Phone: 713-792-6363

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 April 2017
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Disease control rate (DCR) defined as proportion of patients who had complete response, partial response or stable disease by Response Evaluation Criteria in Solid Tumors version 4.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov